2.58
+0.07(+2.79%)
Currency In USD
Address
10 Earlsfort Terrace
Dublin, D02 T380
Ireland
Phone
353 1 905 8020
Sector
Healthcare
Industry
Biotechnology
Employees
116
First IPO Date
November 16, 2023
| Name | Title | Pay | Year Born |
| Ms. Caroline J. Loew Ph.D. | President, Chief Executive Officer & Director | 1.01M | 1971 |
| Mr. Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 735,250 | 1975 |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer | 987,250 | 1971 |
| Ms. Maiken Keson-Brookes | Chief Legal Officer | 0 | 1973 |
| Mr. Justin Levine | Head of Human Resources & Vice President of Human Resources | 0 | N/A |
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.